Other GLP-1 receptor agonists that are FDA-approved to treat type 2 diabetes and may lead to weight loss include: Dulaglutide (Trulicity) Exenatide (Bydureon) Lixisenatide (Adlyxin) Other forms of semaglutide (Ozempic and Rybelsus) Many diabetes medications and insulin reduce blood sugars but also contribute to weight gain
The meta-analysis of 21 trials (PIONEER and SUSTAIN) with 12,260 semaglutide users and 14,176 comparators was funded by the Shenzhen Key Medical Discipline Construction Fund
95% CI, 0.3-0.4
The only GLP-1 formula with probiotics, an essential factor for GLP-1 long-term maintenance, and fenugreek which helps slow down carbohydrate digestion and absorption, enhancing GLP-1 secretion
Caroline Apovian, the co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, agrees: "The studies show over and over and over again," Apovian says, that if you stop taking the medications, "you will regain the weight back." Noom isn't the only startup to market GLP-1s as temporary treatments that offer long-term effects
43% of large employers now cover for weight loss, up from 28% in 2024.[7] If denied, appeal it 82% of appeals are overturned
